Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial

Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-negative breast cancer

Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum-containing regimen

Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in pts with NSCLC

RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy to treat prostate cancer

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma

Nivolumab ipilimumab combo does not improve DFS for RCC after nephrectomy

Pembro + CRT in HNSCC fails to deliver statistically significant event-free survival improvement

Hyperthermic intraperitoneal chemo for locally advanced colon cancer

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan

Extended adjuvant AI not advised for HPBC after 5+ yrs of sequential endocrine therapy

Atezolizumab added to chemo fails to improve PFS in relapsed ovarian cancer